Corona Remedies is set to list on December 15, with a robust grey market premium signaling a strong debut. Heavy oversubscription across investor categories and steady GMP momentum point to healthy listing gains. Price band and issue details suggest solid interest, with estimates placing potential listing near premium-indicated levels.
Shares of Corona Remedies will list on the BSE and NSE on Monday, December 15, with the grey market premium indicating a buoyant debut after significant investor demand across segments in the public issue. The IPO saw massive subscription, reflecting strong appetite for the company’s fundamentals and sector outlookMint.
GMP trends have remained elevated in the run-up to listing, with recent prints suggesting double‑digit percentage gains over the upper price band. Market chatter pegs the implied listing levels notably above issue price, supported by consistent premium movement in the unlisted market.
Key offer details include the price band and an entirely offer-for-sale structure, with listing timelines and allotment already completed. The steady build-up in GMP, alongside oversubscription, has raised expectations for a positive first-day performance.
Important points
Listing date: December 15 on BSE and NSE.
Subscription buzz: IPO saw heavy demand; oversubscription signaled strong interest.
GMP signal: Premium indicated potential double‑digit listing gains vs issue price.
Issue construct: Book-built, entirely offer-for-sale; issue size about ₹655 crore.
Price band: Upper band around ₹1,062, with reports noting ₹1,008–₹1,066 range.
Conclusion
With oversubscription momentum and a firm GMP into listing day, Corona Remedies appears primed for a strong debut. While grey market signals are informal, they reflect sentiment that, together with fundamentals, could drive solid opening performance.
Sources: Livemint; Financial Express; IPOWatch; Chittorgarh